PURPOSE: The goal of this study was to evaluate the ability of nanoparticles to be used as a targeted delivery system for oligonucleotides. METHODS: Pharmacokinetic and tissue distribution were carried out in mice by measuring radioactivity associated to the model oligothymidylate 33P-pdT16 loaded to poly(isobutylcyanoacryate) (PIBCA) nanoparticles. In addition, we have used a TLC linear analyzer to measure quantitatively on a polyacrylamide gel electrophoresis, the amount of non degraded pdT16. RESULTS: Organ distribution study has shown that nanoparticles deliver 33P-pdT16 specifically to the liver reducing its distribution in the kidney and in the bone marrow. Nanoparticles could partially protect pdT16 against degradation in the plasma and in the liver 5 min after administration, whereas free oligonucleotide was totally degraded at the same time. CONCLUSIONS: Nanoparticles protect oligonucleotides in vivo against degradation and deliver them to the liver.
PURPOSE: The goal of this study was to evaluate the ability of nanoparticles to be used as a targeted delivery system for oligonucleotides. METHODS: Pharmacokinetic and tissue distribution were carried out in mice by measuring radioactivity associated to the model oligothymidylate 33P-pdT16 loaded to poly(isobutylcyanoacryate) (PIBCA) nanoparticles. In addition, we have used a TLC linear analyzer to measure quantitatively on a polyacrylamide gel electrophoresis, the amount of non degraded pdT16. RESULTS: Organ distribution study has shown that nanoparticles deliver 33P-pdT16 specifically to the liver reducing its distribution in the kidney and in the bone marrow. Nanoparticles could partially protect pdT16 against degradation in the plasma and in the liver 5 min after administration, whereas free oligonucleotide was totally degraded at the same time. CONCLUSIONS: Nanoparticles protect oligonucleotides in vivo against degradation and deliver them to the liver.
Authors: V Lenaerts; P Couvreur; D Christiaens-Leyh; E Joiris; M Roland; B Rollman; P Speiser Journal: Biomaterials Date: 1984-03 Impact factor: 12.479
Authors: Katherine Perschbacher; John A Smestad; Justin P Peters; Miranda M Standiford; Aleksandar Denic; Bharath Wootla; Arthur E Warrington; Moses Rodriguez; L James Maher Journal: Nucleic Acid Ther Date: 2014-12-23 Impact factor: 5.486